Human protein C concentrate in pediatric septic patients

Giovanni Landoni, Giacomo Monti, Alberto Facchini, Francesco Cama, Elena Bignami, Luca Cabrini, Federico Pappalardo, Alberto Zangrillo

Research output: Contribution to journalArticle

Abstract

Severe sepsis and septic shock are leading causes of morbidity and mortality in the pediatric population. Unlike what is suggested for the adult population, recombinant human activated protein C (rhAPC) is contraindicated in children. Long before rhAPC was considered for use in pediatric patients, case reports appeared on the safe administration of protein C zymogen. Therefore, we conducted a systemic review of currently available data on protein C zymogen (PC) use among children affected by severe sepsis or septic shock. A total number of 13 case series or case reports and a dose-finding study were found on the use of PC in the pediatric intensive care unit, reporting on 118 treated children, with an overall survival of 84%. There was no bleeding complication, the only reported complication being a single mild allergic reaction These studies show that PC is safe, not associated with bleeding and possibly useful for improving coagulation abnormalities of sepsis.

Original languageEnglish
Pages (from-to)13-19
Number of pages7
JournalSigna Vitae
Volume5
Issue number1
Publication statusPublished - 2010

Keywords

  • Drug therapy
  • Pediatric
  • Protein C
  • Review
  • Sepsis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Fingerprint Dive into the research topics of 'Human protein C concentrate in pediatric septic patients'. Together they form a unique fingerprint.

  • Cite this